Lassen Therapeutics
9 known investors
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
Founders & leadership
DK
David KingCo-Founder & CSO
MF
Maria FardisCEO
CC
Cadmus C. RichChief Medical Officer
ES
Elaine StrackerGeneral Counsel
Investors · 9
Alta PartnersJackson · $1M – $12M
Catalio Capital Management, LPNew York
DC Investment PartnersMcLean · $10M
Longitude CapitalMenlo Park · $10M – $30M
Longwood FundBoston
Biotechnology Value FundreportedSan Francisco
Catalio Capital ManagementreportedNew York
Frazier Healthcare PartnersreportedSeattle · $50M – $400M
Frazier Life SciencesreportedPalo Alto
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJan 2024
Frazier Life Sciences (lead), Longitude Capital (lead), Alta Partners, BVF Partners, Catalio Capital Management, Longwood Fund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Lassen Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Lassen Therapeutics do?
- Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
- Who are Lassen Therapeutics's investors?
- Lassen Therapeutics's investors include Alta Partners, Catalio Capital Management, LP, DC Investment Partners, Longitude Capital, Longwood Fund, Biotechnology Value Fund, Catalio Capital Management, Frazier Healthcare Partners and 1 more.